HISTORICAL FACTS: Cdna | History Defined

CareDx Stock Is Up 300% Over the Past Year. Here’s How Much Upside Is Left.

CareDx (CDNA) has surged 300% over the past year, driven by robust technical momentum and strong buy signals. CDNA is rated a “Strong Buy” by several analysts, with consensus price targets suggesting up to 12% further upside. Revenue is projected to grow 30.38% this year, with earnings expected to rise...

Barchart · Aug 10

CareDx Sharpens Precision Diagnostics Push With Naveris Deal, AlloHeme Plans

CareDx (NASDAQ:CDNA) executives outlined the company’s strategy to focus on precision diagnostics, expand into minimal residual disease testing and improve profitability during a Goldman Sachs-hosted discussion. Chief Executive Officer John Hanna said CareDx has reshaped its portfolio around areas

MarketBeat · Jun 9

CareDx Highlights 39% Q1 Growth, Naveris Oncology Push at Jefferies

CareDx (NASDAQ:CDNA) executives outlined the company’s growth strategy, first-quarter performance and pipeline priorities during a presentation at the Jefferies Healthcare Conference, emphasizing transplant diagnostics, specialty oncology and digital workflow integration. John Hanna, chief executiv

MarketBeat · Jun 7